MedTrace Logo

Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC

NCT06356701 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-04-10

No results posted yet for this study

Summary

A Single-center, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Tumor Nutritional Therapy Combined With Immune Checkpoint Inhibitors and Chemotherapy in the First-line Treatment of Stage IV NSCLC Without Driver Gene Mutations

Conditions

  • Long-Term Effects Secondary to Cancer Therapy

Interventions

DIETARY_SUPPLEMENT

Cancer nutritional treatment regimen (Spirulina Bifidobacterium Capsules, Fish Oil Grape Seed Blueberry Soft Capsules, Ganoderma Spore Oil Soft Capsules)

Medication for Research : * Spirulina Bifidobacterium Capsules * Fish Oil Grape Seed Blueberry Soft Capsules; * Ganoderma Lucidum Sporoderm Oil Soft Capsules; oral administration. non-squamous cell carcinoma Drug: Pemetrexed+Cisplatin (or carboplatin) * Sintilimab Injection/Camrelizumab/Tislelizumab/Atezolizumab Injection IV infusion squamous cell carcinoma Drug:Paclitaxel+ Cisplatin (or carboplatin) * Sintilimab Injection/Camrelizumab/Tislelizumab/Atezolizumab Injection IV infusion

Sponsors & Collaborators

  • The First Affiliated Hospital of Dalian Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-15
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06356701 on ClinicalTrials.gov